Compassionate useNeuropeptide
Compound 61673
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061673
Risk Class
MODERATE
Last Audit
Jun 5, 2108
Research Abstract
Neuropeptide candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61673 is a neuropeptide asset inside neuropeptide innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in compassionate use with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061673 with updates logged 2108-06-05.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61673Neuropeptide Program 61673
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061673
- [2] Operations Pulse • Neuropeptide innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61673